The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …

To address the clinical relevance of small DNA variants in chronic myeloid neoplasms
(CMNs), an Association for Molecular Pathology Working Group comprehensively reviewed …

Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …

Abstract In Primary Myelofibrosis (PMF), megakaryocyte dysplasia/hyperplasia determines
the release of inflammatory cytokines that, in turn, stimulate stromal cells and induce bone …

Background Philadelphia negative myeloproliferative neoplasms (MPNs) are characterized
by frequent mutations of driver genes including JAK2, CALR and MPL. While the influence of …

Objectives: To establish the frequency of JAK2, MPL and CALR mutations in Argentinean
patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) and to compare their …

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) in which dysregulation
of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling …

Our insight into the molecular basis of myeloproliferative neoplasms (MPN) took a landmark
stride in 2005 with the identification of JAK2 mutations in nearly all polycythemia vera and …

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by an excessive
production of pro‐inflammatory cytokines resulting in chronic inflammation and genomic …

Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal …